Walgreens Boots Alliance Is Leaving The Nasdaq 100: Is This High-Yield Stock On The Ropes? Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Being pushed out of an index is never a positive thing for a stock. It can be a sign that a company's best days as a strong grower are behind it. Walgreens Boots Alliance (NASDAQ:WBA) has been pushed out of the Nasdaq 100 in favor of fast-moving Super Micro Computer (NASDAQ:SMCI), a hardware company that builds servers. The Nasdaq 100 is an index that tracks the performance of the 100 largest nonfinancial companies on the Nasdaq stock exchange. The companies on the list cover various sectors, from tech to hospitality to pharmaceuticals. Leaving the list may be another sign that Walgreens is flashing a caution sign for dividend investors. Private credit offers up to 20% APY. Potential accredited investors are looking to capitalize on this growing asset class. To be in the Nasdaq 100, companies must have a weighting of at least 0.1% of the Nasdaq 100's market value, now over $20 trillion. Walgreens' stock has fallen by over 56% year to date, paring its market cap down to around $10 billion, which puts it around 0.05%, too small for inclusion. The falling stock price has pumped up Walgreens' forward dividend yield to 8.55%, but that number can be deceptive. The annual dividend is just $1.00 because Walgreens cut its dividend at the start of 2024. Was The Move To Healthcare A Failure? Something dramatic is happening with healthcare in the United States: a move to put more healthcare services in the places we visit most frequently. Large companies, from Walmart (NYSE:WMT) to Kroger (NYSE:KR) and Walgreens' rival CVS (NYSE:CVS), have all experimented with expanding healthcare services in their stores and beyond. Walgreens has spent heavily in this area. In 2022, it spent $8.9 billion to acquire Summit Health-CityMD. The vision expressed by then-CEO Roz Brewer was to combine Summit with Walgreens' existing investments in VillageMD with the expectation that healthcare services would command a larger and larger part of Walgreens' revenue. So far, that grand plan has failed to pay off. The new CEO, Tim Wentworth, is focused on the bottom line and hasn't seen health care pay off as the company had hoped. He's now trying to wind down the company's investment in VillageMD. Speaking with analysts on the most recent earnings call, he stated: "We would continue to have some investment and participate in their growth. It will take time. And as I said, we are looking for a different horizon for what we will invest strategically under our leadership." During that quarter, Walgreens wrote off $5.8 billion in goodwill related to the money it spent on VillageMD. If the all-in-on-healthcare plan exited the company along with the last CEO, what does that mean for the future? Wentworth sees Walgreens' value as centered on its core retail and pharmacy businesses. "The bottom line is that I'm confident WBA will be a leader in the future of health care with pharmacy and retail at its center," said Wentworth. "And the long-term potential of the company will be shaped by offerings built around the relationship that we’ve nurtured with our customers over time." For investors, that means we should think about Walgreens more as a retail company, as judged by sales within its stores. For the most recent quarter, sales were up 2.6%, much of which was driven by pharmacy growth as retail declined. The company is in the midst of a plan to close underperforming stores and shore up the pharmacy business. Will it pay off? Sentiment in the market is relatively negative. Short interest in Walgreens recently spiked to 9.39%, and in the last month, a dozen analysts have lowered their price targets. Trending: Mark Cuban believes “the next wave of revenue generation is around real estate and entertainment” — this new real estate fund allows you to get started with just $100. Is The Rival A Safer Bet? It hasn't been an easy few years for the pharmacy business. After the rush from the pandemic vaccine boom wore off, pharmacies struggled with lower traffic and fewer sales. Rite Aid filed for bankruptcy in 2023 and announced closing more stores nationwide. CVS (NYSE:CVS) may still appeal to investors. While its forward dividend yield is a far lower 4.53%, it raised its quarterly dividend to $0.67 this year. Like Walgreens, CVS has invested heavily in health care, which has slowly paid off. Its last quarter disappointed the market, and CVS lowered its earnings per share guidance. Short interest in this stock is far lower, a mere 1.47%, and analysts are far more optimistic about its prospects with an overall consensus Buy rating. The transition to health care is no sure thing, and some of the big companies above have already scaled back operations. In April, Walmart decided to close its clinics, and Amazon also scaled back its ambitions. CVS may be best positioned to turn clinic health care into a profitable business model, but investors will want to weigh that risk carefully before making a purchase. Check Out One Of Benzinga's Top Picks for Private Market Opportunities Available Now: Integris Secured Credit Fund IV The fund provides a fixed annual return of 12%, payable quarterly, over a 2-year period starting April 2024 and ending April 2026. The note is secured by collateral with an estimated value of $71M, with an anticipated loan-to-value ratio of 14%. Minimum investment: $100,000 Available to: Accredited investors View fund information View more private market offerings on Benzinga's Alternative Investment screener. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article Walgreens Boots Alliance Is Leaving The Nasdaq 100: Is This High-Yield Stock On The Ropes? originally appeared on Benzinga.com
Walgreens Boots Alliance Is Leaving The Nasdaq 100: Is This High-Yield Stock On The Ropes?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...